AAAAAA

   
Results: 1-25 | 26-32
Results: 1-25/32
MEDICO-ECONOMIC ANALYSIS OF DIACEREIN WITH OR WITHOUT STANDARD THERAPY IN THE TREATMENT OF OSTEOARTHRITIS
Authors: FAGNANI F BOUVENOT G VALAT JP BARDIN T BERDAH L LAFUMA A BONO I ESCHWEGE E DREISER RL
Citation: F. Fagnani et al., MEDICO-ECONOMIC ANALYSIS OF DIACEREIN WITH OR WITHOUT STANDARD THERAPY IN THE TREATMENT OF OSTEOARTHRITIS, PharmacoEconomics, 13(1), 1998, pp. 135-146
SHORT-TERM EVALUATION OF PERIRADICULAR CORTICOSTEROID INJECTIONS IN THE TREATMENT OF LUMBAR RADICULOPATHY ASSOCIATED WITH DISC DISEASE
Authors: VITON JM RUBINO T PERETTIVITON P BOUVENOT G DELARQUE A
Citation: Jm. Viton et al., SHORT-TERM EVALUATION OF PERIRADICULAR CORTICOSTEROID INJECTIONS IN THE TREATMENT OF LUMBAR RADICULOPATHY ASSOCIATED WITH DISC DISEASE, Revue du rhumatisme, 65(3), 1998, pp. 195-200
INAPPROPRIATENESS AND VARIABILITY OF ANTIBIOTIC PRESCRIPTION AMONG FRENCH OFFICE-BASED PHYSICIANS
Authors: GUILLEMOT D CARBON C VAUZELLEKERVROEDAN F BALKAU B MAISON P BOUVENOT G ESCHWEGE E
Citation: D. Guillemot et al., INAPPROPRIATENESS AND VARIABILITY OF ANTIBIOTIC PRESCRIPTION AMONG FRENCH OFFICE-BASED PHYSICIANS, Journal of clinical epidemiology, 51(1), 1998, pp. 61-68
THE FRAGILE NATURE OF SCIENTIFICALLY ACQU IRED DATA - THE EXAMPLE OF FLUORIDE SALTS FOR OSTEOPOROSIS
Authors: VILLANI P BONDINORIQUIER R BOUVENOT G
Citation: P. Villani et al., THE FRAGILE NATURE OF SCIENTIFICALLY ACQU IRED DATA - THE EXAMPLE OF FLUORIDE SALTS FOR OSTEOPOROSIS, La Presse medicale, 27(8), 1998, pp. 361-362
ASSESSMENT OF THE PLACEBO-EFFECT OF SYMPT OMATIC SLOW-ACTING DRUGS GIVEN FOR OSTEOARTHRITIS
Authors: VILLANI P BOUVENOT G
Citation: P. Villani et G. Bouvenot, ASSESSMENT OF THE PLACEBO-EFFECT OF SYMPT OMATIC SLOW-ACTING DRUGS GIVEN FOR OSTEOARTHRITIS, La Presse medicale, 27(5), 1998, pp. 211-214
CHANGING THERAPEUTICS OR CLONING PRESCRIPTORS
Authors: BOUVENOT G
Citation: G. Bouvenot, CHANGING THERAPEUTICS OR CLONING PRESCRIPTORS, La Presse medicale, 27(26), 1998, pp. 1330-1331
RECOMMENDATIONS FOR THE REGISTRATION OF DRUGS USED IN THE TREATMENT OF RHEUMATOID-ARTHRITIS
Authors: LEMMEL EM REID DM NUKI G AVOUAC B BARDIN T BOUVENOT G CAUWENBERGE H CLUZEL M DEVOLGELAER JP DUFF GW EMERY P ETHGEN D KREUTZ G MENKES CJ REIDEL H SERNI U VANDERAUWERA P VEYS E WHITEGUAY B REGINSTER JY
Citation: Em. Lemmel et al., RECOMMENDATIONS FOR THE REGISTRATION OF DRUGS USED IN THE TREATMENT OF RHEUMATOID-ARTHRITIS, British journal of rheumatology, 37(2), 1998, pp. 211-215
LOW-DOSAGE AND LONG TREATMENT DURATION OF BETA-LACTAM - RISK-FACTORS FOR CARRIAGE OF PENICILLIN-RESISTANT STREPTOCOCCUS-PNEUMONIAE
Authors: GUILLEMOT D CARBON C BALKAU B GESLIN P LECOEUR H VAUZELLEKERVROEDAN F BOUVENOT G ESCHWEGE E
Citation: D. Guillemot et al., LOW-DOSAGE AND LONG TREATMENT DURATION OF BETA-LACTAM - RISK-FACTORS FOR CARRIAGE OF PENICILLIN-RESISTANT STREPTOCOCCUS-PNEUMONIAE, JAMA, the journal of the American Medical Association, 279(5), 1998, pp. 365-370
TRENDS IN ANTIMICROBIAL DRUG-USE IN THE COMMUNITY - FRANCE, 1981-1992
Authors: GUILLEMOT D MAISON P CARBON C BALKAU B VAUZELLEKERVROEDAN F SERMET C BOUVENOT G ESCHWEGE E
Citation: D. Guillemot et al., TRENDS IN ANTIMICROBIAL DRUG-USE IN THE COMMUNITY - FRANCE, 1981-1992, The Journal of infectious diseases, 177(2), 1998, pp. 492-497
ASSOCIATION OF MILD HYPERHOMOCYSTEINEMIA WITH CARDIAC GRAFT VASCULAR-DISEASE
Authors: AMBROSI P GARCON D RIBERI A HABIB G BARLATIER A KREITMANN B ROLLAND PH BOUVENOT G LUCCIONI R METRAS D
Citation: P. Ambrosi et al., ASSOCIATION OF MILD HYPERHOMOCYSTEINEMIA WITH CARDIAC GRAFT VASCULAR-DISEASE, Atherosclerosis (Amsterdam), 138(2), 1998, pp. 347-350
ELECTROCARDIOGRAPHIC ABNORMALITIES AND AX IS DEVIATION IN HEART-TRANSPLANT RECIPIENTS - MR ASSESSMENT
Authors: AMBROSI P HABIB G GELISSE R YAO J FERRACCI A KREITMANN B METRAS D BERNARD P BOUVENOT G LUCCIONI R
Citation: P. Ambrosi et al., ELECTROCARDIOGRAPHIC ABNORMALITIES AND AX IS DEVIATION IN HEART-TRANSPLANT RECIPIENTS - MR ASSESSMENT, Annales de cardiologie et d'angeiologie, 47(5), 1998, pp. 334-339
A PRAGMATIC COST-EFFECTIVENESS STUDY OF ROUTINE EPIDURAL CORTICOSTEROID INJECTIONS FOR LUMBOSCIATIC SYNDROME REQUIRING INHOSPITAL MANAGEMENT
Authors: LAFUMA A BOUVENOT G COHEN C ESCHWEGE E FAGNANI F VIGNON E
Citation: A. Lafuma et al., A PRAGMATIC COST-EFFECTIVENESS STUDY OF ROUTINE EPIDURAL CORTICOSTEROID INJECTIONS FOR LUMBOSCIATIC SYNDROME REQUIRING INHOSPITAL MANAGEMENT, Revue du rhumatisme, 64(10), 1997, pp. 549-555
INTERMEDIATE AND SURROGATE OUTCOMES IN CL INICAL-EVALUATION OF DRUGS
Authors: BOISSEL JP PERRET L BOUVENOT G CASTAIGNE A GERARDCOUE MJ MAILLERE P MISMETTI P VRAY M AVOUAC B BEGAUD B CAULIN C CHARPAK Y CHAUMETRIFFAUD P COSTAGLIOLA D DEGOS F DESTORS JM DOYON F FAGNANI F GIRI I GIRRE JP GOEHRS JM KHER A MOCCATTI D MUNOZ A DECURZON AP PLETAN Y ROY P VASMANT D WAJMAN A
Citation: Jp. Boissel et al., INTERMEDIATE AND SURROGATE OUTCOMES IN CL INICAL-EVALUATION OF DRUGS, Therapie, 52(4), 1997, pp. 281-285
PLACEBO-CONTROLLED CLINICAL-TRIALS - A REAPPRAISAL
Authors: BOUVENOT G
Citation: G. Bouvenot, PLACEBO-CONTROLLED CLINICAL-TRIALS - A REAPPRAISAL, Revue du rhumatisme, 63(9), 1996, pp. 565-567
WHAT SHOULD OUR TREATMENT DECISIONS BE BASED ON
Authors: BOUVENOT G
Citation: G. Bouvenot, WHAT SHOULD OUR TREATMENT DECISIONS BE BASED ON, Revue du rhumatisme, 63(6), 1996, pp. 383-384
ON THE APPROPRIATE USE OF PHARMACEUTICALS AND THE MEDICAL-PROFESSION
Authors: BOUVENOT G
Citation: G. Bouvenot, ON THE APPROPRIATE USE OF PHARMACEUTICALS AND THE MEDICAL-PROFESSION, La Presse medicale, 25(7), 1996, pp. 269-270
TREND TOWARD EFFICIENCY
Authors: BOUVENOT G
Citation: G. Bouvenot, TREND TOWARD EFFICIENCY, La Presse medicale, 25(28), 1996, pp. 1268-1269
VALIDITY, RELIABILITY, AND SENSITIVITY TO CHANGE OF A FRENCH VERSION OF THE ARTHRITIS IMPACT MEASUREMENT SCALES-2 (AIMS2) IN PATIENTS WITH RHEUMATOID-ARTHRITIS TREATED WITH METHOTREXATE
Authors: POUCHOT J GUILLEMIN F COSTE J BREGEON C SANY J AVOUAC B BARBAZANGES D BONO I BOUVENOT G COHEN C COURCIER S DAVID N DELECOEUILLERIE G DREISER RL DROPSY R DUMONT D GAVROY JP GHEZAIL M HANOTIN C INSUASTY J JOUBERT JM LARBRE JP LASSALE C LAVOIGNAT D MARTY M MEGARD Y MONTANERTAPIA S PAOLOZZI L ROZENBERG S SALLIERE D SANDILLON P STEHLE B THEVENON A LIULEAGE SY SEBERT JL DEHAIS J SCHAEVERBEKE T LEGOFF P LHIRONDEL JL LOYAU G GAUDIN P PHELIP X DELCAMBRE B DUQUESNOY B FLIPO RM ARNAUD M BONNET C TREVES R PERRET P TEBIB J BOUVIER M LLORCA G JORGENSEN C POUREL J BERTHELOT JM PROST A BELLO J ZIEGLER G
Citation: J. Pouchot et al., VALIDITY, RELIABILITY, AND SENSITIVITY TO CHANGE OF A FRENCH VERSION OF THE ARTHRITIS IMPACT MEASUREMENT SCALES-2 (AIMS2) IN PATIENTS WITH RHEUMATOID-ARTHRITIS TREATED WITH METHOTREXATE, Journal of rheumatology, 23(1), 1996, pp. 52-60
RECOMMENDATIONS FOR THE REGISTRATION OF AGENTS USED IN THE PREVENTIONAND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS
Authors: COMPSTON JE AUDRAN M AVOUAC B BOUVENOT G DEVOGELAER JP EASTELL R FABRIS F GENNARI C JONES EA KAUFMAN JM LEMMEL EM MAZZUOLI G REID DM RINGE JD VANHAELST L ZIEGLER R REGINSTER JY
Citation: Je. Compston et al., RECOMMENDATIONS FOR THE REGISTRATION OF AGENTS USED IN THE PREVENTIONAND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS, Calcified tissue international, 59(5), 1996, pp. 323-327
EVIDENCE-BASED MEDICINE
Authors: BOUVENOT G
Citation: G. Bouvenot, EVIDENCE-BASED MEDICINE, Therapie, 51(3), 1996, pp. 209-211
RECOMMENDATIONS FOR THE REGISTRATION OF DRUGS USED IN THE TREATMENT OF OSTEOARTHRITIS
Authors: DOUGADOS M DEVOGELAER JP ANNEFELDT M AVOUAC B BOUVENOT G COOPER C DIEPPE P ETHGEN D GARATTINI S JONES EA KAUFMAN JM LEEMING M LEMMEL EM LOHMANDER S MENKES CJ NUKI G PAOLOZZI L PUJOL JP ROVATI L SERNI U SPECTOR T TSOUDEROS Y VEYS EM WESELOH G REGINSTER JY
Citation: M. Dougados et al., RECOMMENDATIONS FOR THE REGISTRATION OF DRUGS USED IN THE TREATMENT OF OSTEOARTHRITIS, Annals of the Rheumatic Diseases, 55(8), 1996, pp. 552-557
WE HAVE TO HAVE PRAGMATIC TRIALS
Authors: VRAY M BOUVENOT G
Citation: M. Vray et G. Bouvenot, WE HAVE TO HAVE PRAGMATIC TRIALS, La Presse medicale, 24(22), 1995, pp. 1011-1012
RECOMMENDATIONS FOR THE REGISTRATION OF NEW CHEMICAL ENTITIES USED INTHE PREVENTION AND TREATMENT OF OSTEOPOROSIS
Authors: COMPSTON JE REGINSTER JY JONES EA KAUFMAN JM AUDRAN M BOUVENOT G FRATI L MAZZUOLI G GENNARI C LEMMEL EM RINGE JD SEBERT JL VANHAELST L AVOUAC B
Citation: Je. Compston et al., RECOMMENDATIONS FOR THE REGISTRATION OF NEW CHEMICAL ENTITIES USED INTHE PREVENTION AND TREATMENT OF OSTEOPOROSIS, Calcified tissue international, 57(4), 1995, pp. 247-250
PAIN OR PAINS IN THE LUMBAR REGION
Authors: BOUVENOT G
Citation: G. Bouvenot, PAIN OR PAINS IN THE LUMBAR REGION, Revue du rhumatisme, 61(4BIS), 1994, pp. 66-67
CONSIDERATIONS ON THE METHODOLOGY OF STUD IES EVALUATING TREATMENTS FOR OSTEOARTHRITIS
Authors: BOUVENOT G
Citation: G. Bouvenot, CONSIDERATIONS ON THE METHODOLOGY OF STUD IES EVALUATING TREATMENTS FOR OSTEOARTHRITIS, Revue du rhumatisme, 61(2), 1994, pp. 81-84
Risultati: 1-25 | 26-32